LT3445767T - Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui - Google Patents

Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui

Info

Publication number
LT3445767T
LT3445767T LTEP17720720.6T LT17720720T LT3445767T LT 3445767 T LT3445767 T LT 3445767T LT 17720720 T LT17720720 T LT 17720720T LT 3445767 T LT3445767 T LT 3445767T
Authority
LT
Lithuania
Prior art keywords
mcl
cancer
macrocyclic inhibitors
macrocyclic
inhibitors
Prior art date
Application number
LTEP17720720.6T
Other languages
English (en)
Lithuanian (lt)
Inventor
Alexander Hird
Matthew BELMONTE
Wenzhan YANG
John Secrist
Daniel Robbins
Steven KAZMIRSKI
Dedong Wu
Bo Peng
Jeffrey Johannes
Michelle Lamb
Qing Ye
Xiaolan Zheng
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of LT3445767T publication Critical patent/LT3445767T/lt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D497/00Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D497/22Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D515/00Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D515/22Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
LTEP17720720.6T 2016-04-22 2017-04-21 Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui LT3445767T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662326156P 2016-04-22 2016-04-22
PCT/EP2017/059511 WO2017182625A1 (en) 2016-04-22 2017-04-21 Macrocyclic mcl1 inhibitors for treating cancer

Publications (1)

Publication Number Publication Date
LT3445767T true LT3445767T (lt) 2020-05-25

Family

ID=58664658

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP17720720.6T LT3445767T (lt) 2016-04-22 2017-04-21 Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui

Country Status (38)

Country Link
US (4) US9840518B2 (enExample)
EP (1) EP3445767B1 (enExample)
JP (1) JP6894449B2 (enExample)
KR (1) KR102388208B1 (enExample)
CN (1) CN109071566B (enExample)
AR (1) AR108301A1 (enExample)
AU (1) AU2017252222B2 (enExample)
BR (1) BR112018070677B1 (enExample)
CA (1) CA3020378A1 (enExample)
CL (1) CL2018002410A1 (enExample)
CO (1) CO2018008759A2 (enExample)
CR (1) CR20180499A (enExample)
CY (1) CY1123186T1 (enExample)
DK (1) DK3445767T3 (enExample)
DO (1) DOP2018000222A (enExample)
EA (1) EA036551B1 (enExample)
ES (1) ES2791319T3 (enExample)
HR (1) HRP20200673T1 (enExample)
HU (1) HUE049591T2 (enExample)
IL (1) IL262237B (enExample)
LT (1) LT3445767T (enExample)
MA (1) MA44721B1 (enExample)
ME (1) ME03729B (enExample)
MX (1) MX386103B (enExample)
NI (1) NI201800093A (enExample)
PE (1) PE20181803A1 (enExample)
PH (1) PH12018502227A1 (enExample)
PL (1) PL3445767T3 (enExample)
PT (1) PT3445767T (enExample)
RS (1) RS60257B1 (enExample)
SG (1) SG11201805838UA (enExample)
SI (1) SI3445767T1 (enExample)
SM (1) SMT202000249T1 (enExample)
SV (1) SV2018005742A (enExample)
TN (1) TN2018000319A1 (enExample)
TW (1) TWI742074B (enExample)
WO (1) WO2017182625A1 (enExample)
ZA (1) ZA201807766B (enExample)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3411046B1 (en) 2016-02-04 2025-07-16 The Johns Hopkins University Rapaglutins, novel inhibitors of glut and use thereof
AU2017214557B2 (en) 2016-02-04 2022-05-19 The Johns Hopkins University Rapadocins, inhibitors of equilibrative nucleoside transporter 1 and uses thereof
US11066416B2 (en) 2016-02-04 2021-07-20 The Johns Hopkins University Rapafucin derivative compounds and methods of use thereof
MX386103B (es) 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.
US10981932B2 (en) 2016-05-19 2021-04-20 Bayer Aktiengesellschaft Macrocyclic indole derivatives
TWI781996B (zh) * 2017-03-31 2022-11-01 瑞典商阿斯特捷利康公司 合成mcl-1抑制劑之方法
TW201904976A (zh) * 2017-03-31 2019-02-01 瑞典商阿斯特捷利康公司 Mcl-1抑制劑及其使用方法
CN111818917A (zh) 2017-08-15 2020-10-23 艾伯维公司 大环mcl-1抑制剂和使用方法
US20200255451A1 (en) * 2017-08-15 2020-08-13 Abbvie Inc. Macrocyclic mcl-1 inhibitors and methods of use
TWI810220B (zh) 2017-11-17 2023-08-01 德商拜耳廠股份有限公司 經取代之巨環吲哚衍生物
WO2019096909A1 (en) 2017-11-17 2019-05-23 The Broad Institute, Inc. Macrocyclic fluorine substituted indole derivatives as mcl-1 inhibitors, for use in the treatment of cancer
WO2019096914A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
WO2019096907A1 (en) * 2017-11-17 2019-05-23 Bayer Aktiengesellschaft Aryl annulated macrocyclic indole derivatives
US11478451B1 (en) 2017-11-17 2022-10-25 Bayer Aktiengesellschaft Macrocyclic chlorine substituted indole derivatives
UY37973A (es) 2017-11-17 2019-06-28 Bayer Ag Derivados de indol macrocíclicos
TW202014184A (zh) * 2018-04-30 2020-04-16 瑞典商阿斯特捷利康公司 用於治療癌症之組合
JP2022503896A (ja) * 2018-09-30 2022-01-12 ジエンス ヘンルイ メデイシンカンパニー リミテッド インドール大環状誘導体、その調製方法、及びその医薬への応用
TWI810397B (zh) 2018-11-14 2023-08-01 瑞典商阿斯特捷利康公司 治療癌症之方法
CN111205309B (zh) * 2018-11-21 2023-04-07 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
US11691989B2 (en) 2018-11-22 2023-07-04 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic indoles as Mcl-1 inhibitors
US12319703B2 (en) 2019-01-23 2025-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Macrocyclic fused pyrazoles as Mcl-1 inhibitors
KR20210153051A (ko) * 2019-03-08 2021-12-16 제노 매니지먼트, 인크. 매크로사이클릭 화합물
CN113574058B (zh) * 2019-04-30 2024-04-16 江苏恒瑞医药股份有限公司 吲哚类大环衍生物、其制备方法及其在医药上的应用
KR20220006613A (ko) 2019-05-10 2022-01-17 얀센 바이오테크 인코포레이티드 마크로사이클릭 킬레이터 및 이의 사용 방법
US12338250B2 (en) 2019-05-17 2025-06-24 The Broad Institute, Inc. Methods of preparing macrocyclic indoles
CN114728076A (zh) 2019-05-20 2022-07-08 诺华股份有限公司 Mcl-1抑制剂抗体-药物缀合物及使用方法
KR20220024694A (ko) * 2019-06-21 2022-03-03 얀센 파마슈티카 엔.브이. Mcl-1의 거대환식 억제제
WO2021005043A1 (en) 2019-07-09 2021-01-14 Janssen Pharmaceutica Nv Macrocyclic spirocycle derivatives as mcl-1 inhibitors
US20220372014A1 (en) * 2019-10-01 2022-11-24 The Johns Hopkins University Neuroprotective compounds and methods of use thereof
WO2021092053A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Mcl-1 inhibitor macrocycle compounds for use in clinical management of conditions caused or mediated by senescent cells and for treating cancer
WO2021092061A1 (en) * 2019-11-08 2021-05-14 Unity Biotechnology, Inc. Combination treatment for senescence-associated diseases
WO2021099579A1 (en) 2019-11-21 2021-05-27 Janssen Pharmaceutica Nv Macrocyclic indole derivatives as mcl-1 inhibitors
MX2022006180A (es) 2019-11-21 2022-06-14 Janssen Pharmaceutica Nv Derivados macrociclicos de sulfonilo como inhibidores de mcl-1.
CA3162963A1 (en) * 2019-12-18 2021-06-24 Zeno Management, Inc. Macrocyclic compounds
JP2023514364A (ja) * 2020-02-21 2023-04-05 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1の阻害剤としての大環状インドール誘導体
TW202144368A (zh) * 2020-03-30 2021-12-01 大陸商江蘇恒瑞醫藥股份有限公司 吲哚類大環衍生物的結晶形式及其製備方法
EP4157852A1 (en) 2020-05-29 2023-04-05 JANSSEN Pharmaceutica NV Macrocyclic 7-pyrazol-5-yl-indole derivatives as inhibitors of mcl-1
MX2022015998A (es) * 2020-06-19 2023-04-12 Janssen Pharmaceutica Nv Derivados de 4-(pirazol-5-il)-indol macrocíclico unidos a n como inhibidores de mcl-1.
WO2021255257A1 (en) 2020-06-19 2021-12-23 Janssen Pharmaceutica Nv N-linked macrocyclic 7-(pyrazol-5-yl)-indole derivatives as inhibitors of mcl-1
CA3184877A1 (en) 2020-07-08 2022-01-13 Benoit Christian Albert Ghislain De Boeck Macrocyclic ether containing indole derivatives as inhibitors of mcl-1
WO2022032284A1 (en) * 2020-08-07 2022-02-10 Zeno Management, Inc. Macrocyclic compounds
KR20230138444A (ko) 2020-11-24 2023-10-05 노파르티스 아게 Mcl-1 억제제 항체-약물 접합체 및 사용 방법
EP4008324A1 (en) 2020-12-07 2022-06-08 Cellestia Biotech AG Combinations comprising an inhibitor of an anti-apoptotic protein, such as bcl-2, bcl-xl, bclw or mcl-1, and a notch signaling pathway inhibitor for treating cancer
JP2023553719A (ja) 2020-12-17 2023-12-25 ヤンセン ファーマシューティカ エヌ.ベー. Mcl-1阻害剤としての分岐大環状4-(ピラゾール-5-イル)-インドール誘導体
JP2024506648A (ja) 2021-02-12 2024-02-14 ヤンセン ファーマシューティカ エヌ.ベー. がんの治療のためのmcl-1阻害剤としての大環状1,3-架橋6-クロロ-7-ピラゾール-4-イル-1h-インドール-2-カルボキシレート及び6-クロロ-7-ピリミジン-5-イル-1h-インドール-2-カルボキシレート誘導体
WO2022251247A1 (en) * 2021-05-28 2022-12-01 Zeno Management, Inc. Macrocyclic compounds
US11931424B2 (en) 2021-06-11 2024-03-19 Gilead Sciences, Inc. Combination MCL-1 inhibitors with anti-body drug conjugates
WO2022261301A1 (en) 2021-06-11 2022-12-15 Gilead Sciences, Inc. Combination mcl-1 inhibitors with anti-cancer agents
CN115490708B (zh) * 2021-06-18 2025-01-24 苏州亚盛药业有限公司 磺酰胺类大环衍生物及其制备方法和用途
US20240401146A1 (en) 2021-10-06 2024-12-05 Institut National de la Santé et de la Recherche Médicale Methods for predicting and improving the efficacy of mcl-1 inhibitor therapy
KR20250027285A (ko) 2022-05-20 2025-02-25 노파르티스 아게 항신생물 화합물의 항체-약물 접합체 및 그의 사용 방법
WO2025111431A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd7 antibody-drug conjugates and methods of use thereof
WO2025111450A1 (en) 2023-11-22 2025-05-30 Les Laboratoires Servier Anti-cd74 antibody-drug conjugates and methods of use thereof
TW202530255A (zh) 2023-12-15 2025-08-01 法商亞維西亞有限公司 抗il-1rap結合結構域及其抗體-藥物偶聯物

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8445679B2 (en) * 2007-04-16 2013-05-21 Abbvie Inc. 7-substituted indole MCL-1 inhibitors
DK2134685T3 (en) 2007-04-16 2015-12-07 Abbvie Inc 7-unsubstituted indole derivatives as MCL-1 inhibitors
PL2379580T3 (pl) * 2008-12-22 2014-05-30 Merck Sharp & Dohme Nowe środki przeciwbakteryjne do leczenia zakażeń wywołanych bakteriami Gram-dodatnimi
BR112012017756A2 (pt) * 2009-12-23 2016-04-19 Ironwood Pharmaceuticals Inc moduladores crth2
US9284334B2 (en) * 2011-05-19 2016-03-15 Fundación Centro Nacional De Investigaciones Oncologicas Carlos Iii Macrocyclic compounds as protein kinase inhibitors
US10093640B2 (en) 2012-09-21 2018-10-09 Vanderbilt University Substituted benzofuran, benzothiophene and indole MCL-1 inhibitors
US10005728B2 (en) 2013-08-28 2018-06-26 Vanderbilt University Substituted indole Mcl-1 inhibitors
US9944656B2 (en) * 2014-02-12 2018-04-17 VIIV Healthcare UK (No.5) Limited Benzothiazole macrocycles as inhibitors of human immunodeficiency virus replication
WO2015148854A1 (en) 2014-03-27 2015-10-01 Vanderbilt University Substituted indole mcl-1 inhibitors
CA2945237C (en) * 2014-04-11 2022-09-06 Ulrich Lucking Novel macrocyclic compounds
US9949965B2 (en) 2014-10-17 2018-04-24 Vanderbilt University Tricyclic indole Mcl-1 inhibitors and uses thereof
MX386103B (es) 2016-04-22 2025-03-18 Astrazeneca Ab Inhibidores de mcl-1 y metodos de uso de los mismos.

Also Published As

Publication number Publication date
BR112018070677B1 (pt) 2024-02-06
KR102388208B1 (ko) 2022-04-18
HRP20200673T1 (hr) 2020-07-10
JP2019514863A (ja) 2019-06-06
SG11201805838UA (en) 2018-11-29
IL262237B (en) 2021-08-31
MA44721B1 (fr) 2020-05-29
NI201800093A (es) 2019-03-14
US20170305926A1 (en) 2017-10-26
EA036551B1 (ru) 2020-11-23
IL262237A (en) 2018-11-29
DK3445767T3 (da) 2020-05-18
CR20180499A (es) 2019-01-25
PL3445767T3 (pl) 2020-07-13
US20210230184A1 (en) 2021-07-29
ZA201807766B (en) 2021-09-29
MX386103B (es) 2025-03-18
ES2791319T3 (es) 2020-11-03
CO2018008759A2 (es) 2018-09-20
AU2017252222A1 (en) 2018-11-29
MA44721A (fr) 2019-02-27
AU2017252222B2 (en) 2019-11-07
NZ748173A (en) 2025-05-02
PH12018502227A1 (en) 2019-07-29
JP6894449B2 (ja) 2021-06-30
HUE049591T2 (hu) 2020-09-28
PE20181803A1 (es) 2018-11-19
SI3445767T1 (sl) 2020-07-31
CN109071566B (zh) 2021-08-31
TWI742074B (zh) 2021-10-11
DOP2018000222A (es) 2018-10-31
US20190185485A1 (en) 2019-06-20
MX2018012711A (es) 2019-05-30
EP3445767B1 (en) 2020-02-19
CA3020378A1 (en) 2017-10-26
TN2018000319A1 (en) 2020-01-16
CY1123186T1 (el) 2021-10-29
ME03729B (me) 2021-01-20
KR20180135030A (ko) 2018-12-19
AR108301A1 (es) 2018-08-08
EP3445767A1 (en) 2019-02-27
EA201892300A1 (ru) 2019-05-31
SMT202000249T1 (it) 2020-07-08
SV2018005742A (es) 2019-03-25
BR112018070677A2 (pt) 2019-02-05
RS60257B1 (sr) 2020-06-30
TW201803879A (zh) 2018-02-01
PT3445767T (pt) 2020-05-13
CN109071566A (zh) 2018-12-21
US10889594B2 (en) 2021-01-12
US10196404B2 (en) 2019-02-05
US20180155362A1 (en) 2018-06-07
CL2018002410A1 (es) 2018-12-07
US11472816B2 (en) 2022-10-18
WO2017182625A1 (en) 2017-10-26
US9840518B2 (en) 2017-12-12

Similar Documents

Publication Publication Date Title
LT3445767T (lt) Makrocikliniai mcl-1 inhibitoriai, skirti vėžio gydymui
DK3728252T3 (da) 4-azaindolforbindelser
EP3664793A4 (en) MACROCYCLIC IMMUNOMODULATORS
LT3710446T (lt) Junginiai, naudingi cdk7 slopinimui
EP3541932A4 (en) INHIBITORS OF CRISPR-CAS9
LT3157916T (lt) Heteroarilo junginiai, skirti kinazės inhibavimui
HUE054784T2 (hu) 5-klór-2-difluor-metoxifenil-pirazolopirimidin vegyületek, amelyek JAK-gátlók
SI3319969T1 (sl) Diaril makrociklični polimorf
DK3253762T3 (da) 9h-pyrrolo-dipyridinderivater.
DK3374359T3 (da) Dihydroimidazopyrazinonderivater, der er nyttige ved behandling af cancer
IL260082B (en) Small molecules against cancer
LT3402792T (lt) Chinolin-2-ono dariniai
LT3457851T (lt) Sobetiromo dariniai
BR112017001387A2 (pt) alargador.
BR112017001389A2 (pt) alargador.
LT3371168T (lt) Indolin-2-ono dariniai
EP3593139C0 (en) CANCER BIOMARKERS
BR112017001388A2 (pt) alargador.
BR112017001386A2 (pt) alargador.
LT3534885T (lt) Farneziltransferazės inhibitoriai, skirti naudoti vėžio gydymui
LT3386997T (lt) Monomaleimidu funkcionalizuoti platinos junginiai, skirti vėžio terapijai
LT3347360T (lt) Junginiai, naudingi ror-gama-t slopinimui
LT3383385T (lt) Melflufeno dozavimo režimas vėžio atveju
MA46280A (fr) Inhibiteurs de la dopamine-b-hydroxylase
IT201600117182A1 (it) Ribobinatrice.